Does the media refer more to SPRB or PRME?

In the previous week, Prime Medicine had 10 more articles in the media than Spruce Biosciences. MarketBeat recorded 15 mentions for Prime Medicine and 5 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.40 beat Prime Medicine's score of 0.36 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CBIO or SPRB more profitable?

Crescent Biopharma's return on equity of -101.50% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% Spruce Biosciences N/A -123.53% -90.35%

Does the media refer more to CBIO or SPRB?

In the previous week, Crescent Biopharma had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 6 mentions for Crescent Biopharma and 5 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.40 beat Crescent Biopharma's score of 0.34 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EPRX or SPRB more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Spruce Biosciences N/A -123.53% -90.35%

Does the media prefer EPRX or SPRB?

In the previous week, Eupraxia Pharmaceuticals had 5 more articles in the media than Spruce Biosciences. MarketBeat recorded 10 mentions for Eupraxia Pharmaceuticals and 5 mentions for Spruce Biosciences. Eupraxia Pharmaceuticals' average media sentiment score of 0.64 beat Spruce Biosciences' score of 0.40 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PBYI or SPRB?

In the previous week, Spruce Biosciences had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Spruce Biosciences and 4 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.54 beat Spruce Biosciences' score of 0.40 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, KMDA or SPRB?

Kamada has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.78 $20.20M $0.38 22.95 Spruce Biosciences $4.91M 28.48 -$38.97M -$39.78 N/A

Is KMDA or SPRB more profitable?

Kamada has a net margin of 11.60% compared to Spruce Biosciences' net margin of 0.00%. Kamada's return on equity of 8.37% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Spruce Biosciences N/A -123.53% -90.35%

Does the media prefer KMDA or SPRB?

In the previous week, Kamada had 6 more articles in the media than Spruce Biosciences. MarketBeat recorded 11 mentions for Kamada and 5 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.40 beat Kamada's score of -0.72 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Spruce Biosciences (SPRB) Competitors

$48.72 -0.30 (-0.61%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$48.80 +0.09 (+0.17%)

As of 09/25/2026 07:30 PM Eastern

Compare

SPRB vs. PRME, CBIO, EPRX, PBYI, and KMDA

Should you buy Spruce Biosciences stock or one of its competitors? Spruce Biosciences's main competitors and comparable companies include Prime Medicine (PRME), Crescent Biopharma (CBIO), Eupraxia Pharmaceuticals (EPRX), Puma Biotechnology (PBYI), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Spruce Biosciences compare to Prime Medicine?

Spruce Biosciences (NASDAQ:SPRB) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Spruce Biosciences presently has a consensus target price of $158.33, suggesting a potential upside of 224.99%. Prime Medicine has a consensus target price of $7.47, suggesting a potential upside of 157.66%. Given Spruce Biosciences' higher probable upside, research analysts clearly believe Spruce Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Prime Medicine had 10 more articles in the media than Spruce Biosciences. MarketBeat recorded 15 mentions for Prime Medicine and 5 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.40 beat Prime Medicine's score of 0.36 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	2 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spruce Biosciences has a beta of 3.31, indicating that its share price is 231% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

Spruce Biosciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	28.48	-$38.97M	-$39.78	N/A
Prime Medicine	$4.07M	129.14	-$201.14M	-$1.06	N/A

Spruce Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. Spruce Biosciences' return on equity of -123.53% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

Summary

Spruce Biosciences beats Prime Medicine on 10 of the 17 factors compared between the two stocks.

How does Spruce Biosciences compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Crescent Biopharma currently has a consensus price target of $29.60, suggesting a potential upside of 111.58%. Spruce Biosciences has a consensus price target of $158.33, suggesting a potential upside of 224.99%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Crescent Biopharma's return on equity of -101.50% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Spruce Biosciences	N/A	-123.53%	-90.35%

In the previous week, Crescent Biopharma had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 6 mentions for Crescent Biopharma and 5 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.40 beat Crescent Biopharma's score of 0.34 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crescent Biopharma has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, indicating that its stock price is 231% more volatile than the broader market.

Spruce Biosciences has lower revenue, but higher earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$11.88M	43.73	-$153.94M	-$6.72	N/A
Spruce Biosciences	$4.91M	28.48	-$38.97M	-$39.78	N/A

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Crescent Biopharma beats Spruce Biosciences on 9 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Eupraxia Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, meaning that its stock price is 231% more volatile than the broader market.

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Spruce Biosciences. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Spruce Biosciences	$4.91M	28.48	-$38.97M	-$39.78	N/A

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Spruce Biosciences	N/A	-123.53%	-90.35%

Eupraxia Pharmaceuticals currently has a consensus target price of $17.80, suggesting a potential upside of 122.22%. Spruce Biosciences has a consensus target price of $158.33, suggesting a potential upside of 224.99%. Given Spruce Biosciences' higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Eupraxia Pharmaceuticals had 5 more articles in the media than Spruce Biosciences. MarketBeat recorded 10 mentions for Eupraxia Pharmaceuticals and 5 mentions for Spruce Biosciences. Eupraxia Pharmaceuticals' average media sentiment score of 0.64 beat Spruce Biosciences' score of 0.40 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eupraxia Pharmaceuticals beats Spruce Biosciences on 8 of the 15 factors compared between the two stocks.

How does Spruce Biosciences compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, Spruce Biosciences had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Spruce Biosciences and 4 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.54 beat Spruce Biosciences' score of 0.40 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, indicating that its share price is 231% more volatile than the broader market.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.21	$31.11M	$0.52	18.79
Spruce Biosciences	$4.91M	28.48	-$38.97M	-$39.78	N/A

Puma Biotechnology has a net margin of 11.50% compared to Spruce Biosciences' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Spruce Biosciences	N/A	-123.53%	-90.35%

Puma Biotechnology currently has a consensus target price of $6.00, suggesting a potential downside of 38.59%. Spruce Biosciences has a consensus target price of $158.33, suggesting a potential upside of 224.99%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Puma Biotechnology beats Spruce Biosciences on 9 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Kamada?

Kamada (NASDAQ:KMDA) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Kamada has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.78	$20.20M	$0.38	22.95
Spruce Biosciences	$4.91M	28.48	-$38.97M	-$39.78	N/A

Kamada has a net margin of 11.60% compared to Spruce Biosciences' net margin of 0.00%. Kamada's return on equity of 8.37% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Spruce Biosciences	N/A	-123.53%	-90.35%

20.4% of Kamada shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kamada has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, suggesting that its stock price is 231% more volatile than the broader market.

In the previous week, Kamada had 6 more articles in the media than Spruce Biosciences. MarketBeat recorded 11 mentions for Kamada and 5 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.40 beat Kamada's score of -0.72 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada currently has a consensus target price of $13.50, indicating a potential upside of 54.82%. Spruce Biosciences has a consensus target price of $158.33, indicating a potential upside of 224.99%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Kamada beats Spruce Biosciences on 10 of the 16 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$140.02M	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-1.22	14.15	275.82	25.78
Price / Sales	28.48	1,438.70	649.60	92.85
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	1.23	15.28	10.44	6.30
Net Income	-$38.97M	-$22.90M	$3.51B	$360.35M
7 Day Performance	-8.16%	-2.94%	-1.31%	-0.23%
1 Month Performance	-23.03%	-8.80%	-4.61%	-4.16%
1 Year Performance	523.82%	28.99%	15.01%	4.58%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	3.7635 of 5 stars	$48.72 -0.6%	$158.33 +225.0%	+523.8%	$140.02M	$4.91M	N/A	8	News Coverage Analyst Forecast
PRME Prime Medicine	3.3805 of 5 stars	$2.90 -5.7%	$7.47 +158.1%	-43.4%	$525.10M	$4.63M	N/A	146	News Coverage Analyst Forecast Gap Up
CBIO Crescent Biopharma	3.1283 of 5 stars	$14.20 -0.3%	$29.60 +108.4%	+12.6%	$522.75M	$10.84M	N/A	44
EPRX Eupraxia Pharmaceuticals	2.187 of 5 stars	$8.00 -2.0%	$17.80 +122.5%	+39.5%	$519.58M	N/A	N/A	49	News Coverage Analyst Forecast Gap Up High Trading Volume
PBYI Puma Biotechnology	1.1827 of 5 stars	$9.79 -0.3%	$6.00 -38.7%	+101.9%	$504.07M	$228.40M	18.78	179

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. PRME, CBIO, EPRX, PBYI, and KMDA

How does Spruce Biosciences compare to Prime Medicine?

Summary

How does Spruce Biosciences compare to Crescent Biopharma?

Summary

How does Spruce Biosciences compare to Eupraxia Pharmaceuticals?

Summary

How does Spruce Biosciences compare to Puma Biotechnology?

Summary

How does Spruce Biosciences compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. PRME, CBIO, EPRX, PBYI, and KMDA

How does Spruce Biosciences compare to Prime Medicine?

Do analysts recommend SPRB or PRME?

Does the media refer more to SPRB or PRME?

Do insiders and institutionals hold more shares of SPRB or PRME?

Which has more risk & volatility, SPRB or PRME?

Which has higher valuation and earnings, SPRB or PRME?

Is SPRB or PRME more profitable?

Summary

How does Spruce Biosciences compare to Crescent Biopharma?

Do analysts recommend CBIO or SPRB?

Is CBIO or SPRB more profitable?

Does the media refer more to CBIO or SPRB?

Which has more volatility & risk, CBIO or SPRB?

Which has preferable earnings & valuation, CBIO or SPRB?

Do institutionals & insiders hold more shares of CBIO or SPRB?

Summary

How does Spruce Biosciences compare to Eupraxia Pharmaceuticals?

Which has more risk & volatility, EPRX or SPRB?

Do institutionals and insiders hold more shares of EPRX or SPRB?

Which has better earnings & valuation, EPRX or SPRB?

Is EPRX or SPRB more profitable?

Do analysts rate EPRX or SPRB?

Does the media prefer EPRX or SPRB?

Summary

How does Spruce Biosciences compare to Puma Biotechnology?

Does the media refer more to PBYI or SPRB?

Which has more risk & volatility, PBYI or SPRB?

Do institutionals & insiders hold more shares of PBYI or SPRB?

Which has higher earnings and valuation, PBYI or SPRB?

Is PBYI or SPRB more profitable?

Do analysts prefer PBYI or SPRB?

Summary

How does Spruce Biosciences compare to Kamada?

Which has better valuation and earnings, KMDA or SPRB?

Is KMDA or SPRB more profitable?

Do insiders and institutionals believe in KMDA or SPRB?

Which has more volatility and risk, KMDA or SPRB?

Does the media prefer KMDA or SPRB?

Do analysts prefer KMDA or SPRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools